QuidelOrtho Corp QDEL

Healthcare SIC 2835 - In Vitro & In Vivo Diagnostic Substances NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Our vision is to advance diagnostics to power a healthier future. With our expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, we aim to support clarity for clinicians and patients to help create better health outcomes. Our global infrastructure and commercial reach support our customers across more than 140 countries and territories with quality diagnostics, a broad test portfolio and market-leading service. We operate globally with manufacturing facilities in the U.S., U.K. and China and with sales centers, administrative offices and warehouses located throughout the world.

We currently sell our products directly to end users through a direct sales force and through a network of distributors, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, other POC settings, blood banks and donor centers, as well as for individual, non-professional, OTC use.

Last close 13.73 2026-10-23
Market cap $941.5M 2026-06-28 share count
52-week range 9.92 - 35.58

Valuation FY2025 figures against the last close

P/S0.3x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-16.69

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • Domestic
  • Foreign
Revenue by geography, 2 categories over 3 years. The same figures are in the table below. FY2025 Domestic, FY2025: 1.4B (52.6%) 53% Domestic Foreign, FY2025: 1.3B (47.4%) 47% Foreign FY2024 Domestic, FY2024: 1.6B (56.4%) 56% Foreign, FY2024: 1.2B (43.6%) 44% FY2023 Domestic, FY2023: 1.8B (61.0%) 61% Foreign, FY2023: 1.2B (39.0%) 39%
Region FY2025FY2024FY2023
Domestic $1.44B $1.57B $1.83B
Foreign $1.29B $1.21B $1.17B

As the company reported it, from the “Segment and Geographic Information - Geographic Territory (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Revenue by segment

  • North America
  • Emea
  • China
  • Jpac
  • Latin America
Revenue by segment, 5 categories over 3 years. The same figures are in the table below. FY2025 North America, FY2025: 1.5B (54.5%) 55% North America Emea, FY2025: 360.7M (13.2%) 13% Emea China, FY2025: 334.7M (12.3%) 12% China Jpac, FY2025: 293M (10.7%) 11% Jpac Latin America, FY2025: 252.9M (9.3%) 9% Latin America FY2024 North America, FY2024: 1.6B (58.2%) 58% Emea, FY2024: 335.8M (12.1%) 12% China, FY2024: 325M (11.7%) 12% Jpac, FY2024: 279.4M (10.0%) 10% Latin America, FY2024: 222.9M (8.0%) 8% FY2023 North America, FY2023: 1.9B (62.6%) 63% Emea, FY2023: 327.3M (10.9%) 11% China, FY2023: 310.1M (10.3%) 10% Jpac, FY2023: 272.7M (9.1%) 9% Latin America, FY2023: 210.6M (7.0%) 7%
Segment FY2025FY2024FY2023
North America $1.49B $1.62B $1.88B
Emea $360.7M $335.8M $327.3M
China $334.7M $325.0M $310.1M
Jpac $293.0M $279.4M $272.7M
Latin America $252.9M $222.9M $210.6M

As the company reported it, from the “Segment and Geographic Information - Reconciliation to Income (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Segments are the filer's own reporting structure, which is a decision about how it runs itself rather than a standard taxonomy: two companies in the same industry routinely divide themselves along different lines, so these are worth reading down a single company rather than across two. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue $2.73B$2.78B$3.00B$3.27B$1.70B$1.66B—
R&D $186.2M$218.7M$245.0M$187.9M$95.7M$84.3M—
SG&A $746.3M$766.8M$763.2M$621.0M$239.6M$180.7M—
Operating income -$919.2M-$1.96B$139.1M$843.7M$906.0M$1.06B—
Interest expense $177.6M$163.5M$147.6M$75.7M$5.8M$8.5M—
Pre-tax income -$1.11B-$2.13B-$29.1M$735.9M$900.3M$1.04B—
Income tax $24.1M$79.5M$19.0M$187.2M$196.1M$230.0M—
Net income -$1.13B-$2.05B-$10.1M$548.7M$704.2M$810.3M—
EPS, basic -16.69-30.54-0.159.6616.7419.24—
EPS, diluted -16.69-30.54-0.159.5616.4318.60—
Shares, diluted (wtd. avg.) 67.8M67.2M66.8M57.4M42.9M43.6M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents $169.8M$98.3M$119.5M$293.9M$802.8M$489.9M$52.8M
Short-term investments —$0$48.4M$52.1M$25.7M——
Receivables $417.0M$282.4M$303.3M$453.9M$378.0M——
Inventory $577.6M$533.7M$577.8M$524.1M$198.8M——
Total current assets $1.45B$1.22B$1.31B$1.58B$1.44B——
Property, plant and equipment ——$1.44B$1.34B$349.2M——
Goodwill $0$649.5M$2.49B$2.48B$337.0M——
Other intangibles $2.56B$2.74B$2.93B$3.12B$98.7M——
Total assets $5.77B$6.42B$8.56B$8.86B$2.43B——
Accounts payable $279.4M$246.0M$294.8M$283.3M$101.5M——
Short-term debt $178.3M$341.8M$139.8M$207.5M$300.0K——
Total current liabilities $966.1M$998.8M$833.8M$1.01B$323.5M——
Long-term debt $2.70B$2.49B$2.42B$2.65B———
Total liabilities $3.85B$3.44B$3.56B$3.92B$501.0M——
Retained earnings -$996.0M$135.8M$2.19B$2.20B$1.65B——
Total equity $1.92B$2.98B$5.01B$4.93B$1.93B$1.33B$559.9M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Operating cash flow $105.2M$83.0M$280.2M$885.3M$805.9M$629.7M—
Depreciation and amortisation $442.0M$453.4M$457.2M$283.6M$52.7M$48.8M—
Stock-based compensation $45.9M$42.1M$51.6M$48.4M$25.4M$21.0M—
Capital expenditure $188.2M$195.1M$209.3M$140.9M$292.8M$64.9M—
Investing cash flow -$192.7M-$149.9M-$187.6M-$1.64B-$319.5M-$63.3M—
Financing cash flow $155.8M$48.8M-$265.8M$252.0M-$173.1M-$130.3M—
Buybacks $0$0$7.2M$74.3M$103.5M$43.7M—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001906324-26-000018.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -4B -2B 0 2B 4B Revenue, FY2020: 1.7B Net income, FY2020: 810.3M Revenue, FY2021: 1.7B Net income, FY2021: 704.2M Revenue, FY2022: 3.3B Net income, FY2022: 548.7M Revenue, FY2023: 3B Net income, FY2023: -10.1M Revenue, FY2024: 2.8B Net income, FY2024: -2.1B Revenue, FY2025: 2.7B Net income, FY2025: -1.1B FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — $1.66B $1.70B $3.27B $3.00B $2.78B $2.73B
Gross profit — — — — — — —
Net income — $810.3M $704.2M $548.7M -$10.1M -$2.05B -$1.13B

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Regulation FD disclosure Item 7.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Officer or director change Item 5.02
  • Results announced Item 2.02
  • Officer or director change Item 5.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2835

TickerCompanyMarket capP/ERevenue growth
IDXX IDEXX LABORATORIES INC /DE $44.15B 42.8x 10.4%
LNTH Lantheus Holdings, Inc. $6.51B 29.3x 0.5%
NEOG NEOGEN CORP $2.66B — -2.7%
CLDX Celldex Therapeutics, Inc. $2.30B — -78.0%
NTLA Intellia Therapeutics, Inc. $1.57B — 16.9%
ACHV ACHIEVE LIFE SCIENCES, INC. $667.8M — —
MYGN MYRIAD GENETICS INC $556.7M — -1.6%
TKNO Alpha Teknova, Inc. $344.7M — 7.4%